Vyleesi (Bremelanotide) Switching Guide: Moving To or From Other HSDD Treatments

Import from '@/components'

What Is Bremelanotide and How Does Vyleesi Work?

Bremelanotide is a synthetic melanocortin receptor agonist, not a hormone and not a serotonergic antidepressant. It activates melanocortin receptors (specifically MC3R and MC4R) in the central nervous system, which are part of the brain's sexual-motivation circuitry. That central action distinguishes it fundamentally from every other agent a clinician might consider for HSDD.

The Melanocortin Pathway: Why It Matters for Women

The melanocortin system sits at a crossroads of appetite, mood, autonomic tone, and sexual behavior. In animal models and early human data, MC4R activation in the hypothalamus increases dopaminergic signaling in pathways that govern sexual motivation, without directly touching estrogen or testosterone receptors. This is why bremelanotide can produce a desire response even when a woman's ovarian hormone levels are normal, or in some clinical situations where hormonal manipulation has already been tried.

This mechanism also explains the drug's most characteristic side effects: nausea (reported in roughly 40% of participants in the RECONNECT trial), flushing, and transient blood-pressure changes. These are melanocortin effects, not estrogen or serotonin effects.

On-Demand vs. Daily: A Structural Difference That Changes Everything

Bremelanotide is taken as needed, typically 45 minutes before anticipated sexual activity. Flibanserin (Addyi), the only other FDA-approved HSDD drug, must be taken every night at bedtime regardless of sexual activity, and carries a boxed warning about severe hypotension and CNS depression when combined with alcohol. The dosing architecture of these two drugs reflects completely different pharmacological strategies, and that difference shapes every switching decision.

Who Is Bremelanotide Approved For, and Where Does It Sit in HSDD Care?

The FDA approved bremelanotide in June 2019 specifically for premenopausal women with acquired, generalized HSDD. "Acquired" means the disorder developed after a period of normal sexual desire. "Generalized" means it occurs regardless of partner, situation, or type of stimulation.

Life Stage by Life Stage

Reproductive years (cycling, not trying to conceive). This is the approved population. Bremelanotide is appropriate here as a first-line or second-line option when HSDD is confirmed by validated instruments such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R). The RECONNECT trial enrolled premenopausal women aged 21 to 57 with a mean age of 38, giving solid data in this group.

Trying to conceive. Bremelanotide is contraindicated during pregnancy and should be stopped before any conception attempt. See the full Pregnancy and Lactation section below.

Perimenopause. FDA approval does not extend to perimenopausal or postmenopausal women. Some clinicians use it off-label in perimenopause when HSDD is clearly a central-desire problem rather than a genitourinary syndrome of menopause (GSM) issue, but there are no published randomized trial data in this population specifically. If you are in perimenopause, your prescriber should document that they have considered GSM, low testosterone, depression, and relationship factors before attributing low desire to a primary central HSDD that bremelanotide targets.

Postmenopause. Off-label, evidence-poor. The melanocortin pathway does not depend on estrogen, so a biological rationale exists, but RECONNECT did not include postmenopausal women, and no adequately powered trial in this group has been published.

Conditions That Co-Occur and Complicate the Picture

HSDD in women rarely presents alone. Common co-occurring conditions that affect treatment selection include:

• PCOS. Women with PCOS have higher rates of mood disorders, insulin resistance, and androgen dysregulation, any of which can blunt sexual desire independently of the melanocortin circuit. Addressing testosterone excess, metabolic health, and depression may need to happen before or alongside bremelanotide.
• Endometriosis. Chronic pelvic pain reduces sexual desire through a different mechanism. Bremelanotide addresses central motivation; it does not treat pain-related avoidance.
• Postpartum. Not studied in postpartum women. Prolactin levels after delivery and during lactation suppress libido through separate hypothalamic pathways; bremelanotide's role here is unknown.
• Hormonal acne and cycle-phase variation. Some women report that desire fluctuates with the menstrual cycle. Bremelanotide's as-needed design means a woman can time use to phases when she wants support, rather than taking a daily agent throughout her cycle.

The RECONNECT Trial: What the Evidence Actually Shows

The key data for bremelanotide come from two identically designed Phase 3 trials pooled under the RECONNECT program and published in Obstetrics & Gynecology in 2019. The trials enrolled 1,247 premenopausal women with acquired generalized HSDD. Participants were randomized to 1.75 mg bremelanotide subcutaneous injection as needed versus placebo over 24 weeks.

Key results:

• A statistically significant improvement in the FSDS-R desire-distress score (the co-primary endpoint) was observed for bremelanotide vs. Placebo.
• The FSFI desire domain score also improved significantly.
• Approximately 25% of women in the bremelanotide group reported a meaningful within-patient improvement on the Patient Global Impression of Improvement scale, compared with about 17% on placebo.
• Nausea was the most common adverse event, occurring in about 40% of bremelanotide users, with the majority rating it mild to moderate.
• Transient blood pressure increases (mean systolic rise of approximately 1.7 mmHg, lasting up to 12 hours) were recorded; no serious cardiovascular events were attributed to the drug.

The absolute effect sizes in RECONNECT are modest, which is consistent with the complexity of sexual desire as a construct. The drug works for a subset of women with central-desire deficit. It does not universally restore libido, and patient selection matters considerably.

Switching From Flibanserin to Bremelanotide: A Practical Protocol

No head-to-head trial has compared bremelanotide directly with flibanserin in a switching design. The guidance below synthesizes pharmacological principles, the FDA prescribing information for both agents, and published pharmacokinetic data.

When Switching Makes Clinical Sense

Consider moving from flibanserin to bremelanotide when:

1. Daily pill burden is reducing adherence. Flibanserin must be taken every night; many women find this burdensome when their HSDD is situational or intermittent rather than persistent.
2. Alcohol use is a safety concern. Flibanserin carries a boxed warning: combining it with any amount of alcohol substantially increases the risk of hypotension, syncope, and CNS depression. Women who do not want to abstain from alcohol entirely may find the as-needed dosing of bremelanotide a safer fit for their lifestyle.
3. CNS-sedation side effects are limiting. Flibanserin's serotonin 1A agonism and 2A antagonism cause somnolence and dizziness in a significant minority of users, particularly if bedtime dosing is not strictly observed.
4. The desire problem is clearly situational rather than global. Bremelanotide's on-demand profile aligns better with women whose desire deficits are context-dependent.

Pharmacological Washout Considerations

Flibanserin has a half-life of approximately 11 hours; its active metabolite has a longer half-life of roughly 12 to 17 hours. This means clinically meaningful plasma concentrations of flibanserin are gone within 2 to 3 days of stopping. There is no pharmacokinetic interaction between residual flibanserin and bremelanotide that creates a safety signal, because the two drugs act on entirely different receptor systems.

A washout period is not pharmacologically required. However, most experienced clinicians allow 5 to 7 days between stopping flibanserin and starting bremelanotide simply to establish a clean symptom baseline before the first bremelanotide dose. That is a clinical preference, not a safety rule derived from drug-drug interaction data.

Starting Bremelanotide After Flibanserin

• Confirm the HSDD diagnosis and primary endpoint definition remain valid. A validated FSDS-R score at the time of switching gives you a baseline for comparison.
• Begin at the standard approved dose: 1.75 mg subcutaneous injection in the abdomen, thigh, or upper arm, no more than once per 24 hours.
• Advise the patient to administer the dose approximately 45 minutes before anticipated sexual activity. The drug reaches peak plasma concentration at roughly 1 hour.
• Pre-treat nausea proactively. Unlike flibanserin, bremelanotide's major tolerability issue is nausea. Many clinicians suggest taking a single dose of an over-the-counter antiemetic (ondansetron or meclizine) 30 minutes before the first several injections. This is not in the label but is consistent with the mechanism and widely used in practice.
• Blood pressure check at baseline is reasonable given the small but real transient pressor effect. Bremelanotide is not recommended in women with uncontrolled hypertension or known cardiovascular disease.

Switching From Bremelanotide to Flibanserin

When This Direction Makes Sense

Some women prefer the continuous pharmacological support that daily flibanserin provides over the responsibility of timing an injection. Others find bremelanotide's nausea or injection-site reactions intolerable after a fair trial.

A "fair trial" for bremelanotide is generally considered at least four to eight uses over 4 to 8 weeks, because on-demand drugs require sexual opportunity to demonstrate effect. If a woman has not had sexual activity during her trial period, no conclusion about efficacy is possible.

Transitioning Protocol

Bremelanotide's half-life is approximately 2.7 hours. It is essentially eliminated within 12 hours of a dose. Starting flibanserin the same evening you take your last bremelanotide injection is pharmacologically safe, though again, a 2 to 3 day interval is reasonable practice to allow blood pressure to fully normalize.

When starting flibanserin:

• Begin at the approved dose of 100 mg orally at bedtime.
• Counsel about the alcohol restriction plainly and specifically: the FDA boxed warning covers all alcohol, not just heavy drinking. Even moderate intake within 2 hours of dosing can cause syncope.
• Reassess at 8 weeks. If there is no meaningful improvement in desire and/or distress, the prescribing information recommends discontinuing, and most clinicians agree this timeline is appropriate.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

This section is mandatory reading before you use either HSDD medication.

Pregnancy

Bremelanotide is contraindicated in pregnancy. Animal reproductive studies showed embryo-fetal toxicity, including fetal loss and growth restriction, at doses that produced plasma exposures similar to those seen in humans at the therapeutic dose. No adequate human pregnancy data exist, and none should be pursued.

If you are using bremelanotide and discover you are pregnant, stop immediately and contact your obstetric provider.

Trying to Conceive

Stop bremelanotide before actively trying to conceive. Because the drug is taken as needed rather than daily, the simplest approach is to simply not use it from the point you begin trying. The 2.7-hour half-life means the drug is pharmacokinetically cleared within 12 to 24 hours of any given dose. There is no evidence of accumulation across cycles. Still, because preimplantation and early implantation are sensitive developmental windows, avoiding the drug from the cycle in which you begin trying is the conservative and recommended approach.

Lactation

No human data on bremelanotide transfer into breast milk exist. Melanocortin peptides are large-ish molecules (bremelanotide has a molecular weight of approximately 1,025 g/mol), which may limit passive milk transfer, but this has not been studied in lactating women. Given the absence of safety data and the non-urgent nature of the indication, bremelanotide should not be used during breastfeeding. If HSDD is a significant concern in the postpartum period, speak with your clinician about whether addressing prolactin levels, sleep deprivation, relationship factors, and pelvic floor recovery might address the desire deficit first.

Contraception Requirement

Bremelanotide does not require contraception the way a classic teratogen does (no REMS program mandates pregnancy testing or contraception at dispensing). But the embryo-fetal risk is real enough that any woman who is sexually active and not ready for pregnancy should use reliable contraception while using this drug. The drug's on-demand dosing does not itself prevent pregnancy.

Who This Drug Is Right For, and Who Should Look Elsewhere

Likely Right for You If:

• You have a confirmed diagnosis of acquired, generalized HSDD in the premenopausal period, supported by validated scale scores.
• Your low desire is not fully explained by a treatable underlying cause (thyroid dysfunction, depression, relationship stress, medication-induced desire loss from antidepressants or hormonal contraceptives).
• You prefer dosing only when relevant to sexual activity rather than daily pharmacological support.
• You are not pregnant, not trying to conceive, and not breastfeeding.
• You do not have uncontrolled hypertension or significant cardiovascular disease.

Probably Not Right for You If:

• You are postmenopausal and your low desire is primarily driven by GSM, vaginal dryness, or pain. Local estrogen or ospemifene addresses those mechanisms; bremelanotide does not.
• Your HSDD is medication-induced, specifically from an SSRI or SNRI. Addressing the medication causing the problem (dose reduction, drug holiday with psychiatrist input, switch to bupropion or mirtazapine) is usually the first and most direct intervention.
• You have needle phobia or significant injection-site anxiety that is unlikely to resolve. Subcutaneous self-injection is the only route of administration.
• Your desire deficit is primarily situational, responsive to context, and not causing personal distress. The HSDD diagnosis requires distress; if you are not distressed, the indication does not apply.
• You are perimenopausal and have not yet had a thorough hormonal workup. Low estradiol, low testosterone, high FSH, and disrupted sleep all reduce desire through pathways unrelated to melanocortin signaling.

Sex-Specific Pharmacokinetics: What Your Prescriber Should Know

Women metabolize many drugs differently than men, and this is rarely documented in labeling. Bremelanotide's pharmacokinetic data in the RECONNECT program were collected exclusively in women (the approved population), which means the labeled parameters, peak concentration at roughly 1 hour after subcutaneous injection, half-life of approximately 2.7 hours, primary elimination via peptide hydrolysis rather than hepatic CYP enzymes, reflect female biology without the need for extrapolation. That is an advantage.

CYP enzyme-based drug interactions are minimal with bremelanotide. The drug is not a substrate of CYP3A4, CYP2D6, or other major oxidative pathways. This makes it a practical option for women on CYP-heavy regimens (anticonvulsants, some antifungals) who would face significant interaction risk with drugs that depend on those enzymes.

Menstrual cycle phase has not been formally studied as a pharmacokinetic variable for bremelanotide. Given that the drug's target receptors (MC3R and MC4R) are expressed in the hypothalamus rather than in peripheral reproductive tissue, cycle-phase variation in efficacy is theoretically small, but this has not been directly examined in published literature. Women have historically been under-represented in PK subgroup analyses, and this gap remains.

Practical Injection Guidance and Tolerability Management

Most women who stop bremelanotide do so because of nausea, not because of lack of efficacy. Some clinical strategies that reduce the chance of nausea without any pharmacological intervention:

• Eat a light meal or snack before injecting rather than dosing on an empty stomach.
• Stay well hydrated on the day of planned use.
• Avoid lying flat immediately after injection; remain upright for at least 30 minutes.
• Rotate injection sites between abdomen, thigh, and upper arm to reduce injection-site reactions, which include localized hyperpigmentation in a small percentage of users.

Hyperpigmentation at injection sites and on the face and gums has been reported with repeated bremelanotide use. This side effect is dose-related and tends to be more common with higher frequency of use. Limiting use to the approved maximum of once per 24 hours and not using the drug more frequently than sexual activity actually warrants reduces this risk. If hyperpigmentation appears, discuss with your prescriber; it may not fully reverse after stopping.

A Note on the Evidence Gap in Women's Sexual Health Research

The RECONNECT trial is, as of this writing, one of the few large, female-only randomized controlled trials in sexual medicine. Most sexual dysfunction research historically enrolled primarily male participants and extrapolated to women. The result is that HSDD in women was not even formally classified as a distinct condition separate from male hypoactive sexual desire until the DSM-5 in 2013, and the two approved pharmacological treatments (bremelanotide and flibanserin) represent the entirety of an approved pharmacopoeia built on female-specific data. That is a genuinely narrow evidence base. Any woman considering either drug should understand that the effect sizes, while statistically significant, are modest, and that psychosexual therapy, specifically mindfulness-based cognitive behavioral therapy for sexual desire, has demonstrated comparable or larger effect sizes in trials by Lori Brotto and colleagues, often without the side-effect burden.

Combining pharmacological and behavioral approaches has not been formally studied in a large RCT for bremelanotide. This is a gap that matters.